Skip to Content

Recorlev FDA Approval Status

FDA Approved: No
Brand name: Recorlev
Generic name: levoketoconazole
Company: Strongbridge Biopharma plc
Treatment for: Cushing's Syndrome

Recorlev (levoketoconazole) is an investigational cortisol synthesis inhibitor in development for the treatment of patients with endogenous Cushing’s syndrome.

Development Timeline for Recorlev

DateArticle
Mar  2, 2021Strongbridge Biopharma plc Announces Submission of New Drug Application for Recorlev (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome to the FDA

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.